Walter C. Darbonne

8.0k total citations · 2 hit papers
46 papers, 6.1k citations indexed

About

Walter C. Darbonne is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Walter C. Darbonne has authored 46 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 21 papers in Oncology and 10 papers in Immunology. Recurrent topics in Walter C. Darbonne's work include Lung Cancer Treatments and Mutations (8 papers), Hedgehog Signaling Pathway Studies (7 papers) and Cancer Genomics and Diagnostics (6 papers). Walter C. Darbonne is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Hedgehog Signaling Pathway Studies (7 papers) and Cancer Genomics and Diagnostics (6 papers). Walter C. Darbonne collaborates with scholars based in United States, France and United Kingdom. Walter C. Darbonne's co-authors include Frédéric J. de Sauvage, Richard Horuk, Philip E. Hass, C A Hébert, E. Luis, Patricia LoRusso, Charles M. Rudin, Daniel D. Von Hoff, Jennifer A. Low and Mitesh J. Borad and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Walter C. Darbonne

43 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand

1994 1.1k citations Frédéric J. de Sauvage, Walter C. Darbonne et al. profile →
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

2009 833 citations Daniel D. Von Hoff, Patricia LoRusso et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Walter C. Darbonne United States	26	2.7k	1.9k	1.5k	1.4k	622	46	6.1k
Joost J. van den Oord Belgium	48	2.8k 1.0×	1.9k 1.0×	1.8k 1.2×	854 0.6×	1.1k 1.7×	167	7.8k
Deborah L. French United States	38	2.4k 0.9×	741 0.4×	1.0k 0.7×	1.4k 1.0×	210 0.3×	134	5.3k
Andre C. Schuh Canada	35	4.9k 1.8×	1.4k 0.7×	868 0.6×	2.5k 1.8×	234 0.4×	181	7.8k
Reuben Kapur United States	41	2.8k 1.0×	932 0.5×	2.4k 1.6×	1.3k 1.0×	259 0.4×	172	6.0k
David M. Dorfman United States	41	1.6k 0.6×	1.8k 1.0×	2.4k 1.6×	658 0.5×	539 0.9×	153	6.7k
Lindsey A. Miles United States	41	2.4k 0.9×	724 0.4×	670 0.4×	1.9k 1.3×	365 0.6×	99	6.2k
Hisanori Umehara Japan	47	2.6k 1.0×	1.3k 0.7×	1.8k 1.2×	596 0.4×	2.1k 3.4×	158	7.8k
Kiyohiko Hatake Japan	41	1.3k 0.5×	2.3k 1.2×	1.2k 0.8×	603 0.4×	395 0.6×	237	5.1k
Norio Komatsu Japan	44	2.6k 0.9×	1.2k 0.7×	1.4k 0.9×	2.8k 2.0×	267 0.4×	384	6.7k
Marie‐Pierre Chenard France	38	2.7k 1.0×	2.8k 1.5×	948 0.6×	502 0.4×	524 0.8×	137	6.9k

Countries citing papers authored by Walter C. Darbonne

Since Specialization

Citations

This map shows the geographic impact of Walter C. Darbonne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walter C. Darbonne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walter C. Darbonne more than expected).

Fields of papers citing papers by Walter C. Darbonne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walter C. Darbonne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walter C. Darbonne. The network helps show where Walter C. Darbonne may publish in the future.

Co-authorship network of co-authors of Walter C. Darbonne

This figure shows the co-authorship network connecting the top 25 collaborators of Walter C. Darbonne. A scholar is included among the top collaborators of Walter C. Darbonne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walter C. Darbonne. Walter C. Darbonne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spigel, David R., Maen Hussein, Richard Zuniga, et al.. (2023). MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).. Journal of Clinical Oncology. 41(16_suppl). 2612–2612. 1 indexed citations

Tolaney, Sara M., T. Khanh, Joseph P. Eder, et al.. (2020). A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. Clinical Cancer Research. 26(21). 5588–5597. 15 indexed citations

Halperin, Daniel M., Suyu Liu, Arvind Dasari, et al.. (2020). A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs).. Journal of Clinical Oncology. 38(4_suppl). 619–619. 30 indexed citations

Guan, Yinghui, Oleg Mayba, Thomas Sandmann, et al.. (2017). High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing. Journal of Molecular Diagnostics. 19(6). 921–932. 18 indexed citations

Punnoose, Elizabeth A., Joel Johansson, Franklin Peale, et al.. (2016). Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Molecular Cancer Therapeutics. 15(5). 1132–1144. 223 indexed citations

Modi, Shanu, Joseph P. Eder, Patricia LoRusso, et al.. (2016). A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors. Annals of Oncology. 27. vi114–vi114.

Ilié, Marius, Edith Szafer‐Glusman, Véronique Hofman, et al.. (2015). Abstract 1580: MET expression in circulating tumor cells (CTCs) isolated on the ISET platform correlates with MET expression in matched tumor tissue in advanced NSCLC patients. Cancer Research. 75(15_Supplement). 1580–1580. 1 indexed citations

Brais, Rebecca, Susan E. Davies, Maria O’Donovan, et al.. (2012). Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Pancreatology. 12(1). 8–15. 39 indexed citations

Wong, Harvey, Nageshwar Budha, Kristina West, et al.. (2012). Dogs Are More Sensitive to Antagonists of Inhibitor of Apoptosis Proteins Than Rats and Humans: A Translational Toxicokinetic/Toxicodynamic Analysis. Toxicological Sciences. 130(1). 205–213. 13 indexed citations

10.

Sampath, Deepak, Elizabeth A. Punnoose, Erwin R. Boghaert, et al.. (2012). Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models. Blood. 120(21). 5028–5028. 2 indexed citations

11.

LoRusso, Patricia, Charles M. Rudin, Josina C. Reddy, et al.. (2011). Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 17(8). 2502–2511. 420 indexed citations

12.

Darbonne, Walter C., Xing Du, Punita Dhawan, et al.. (2011). Mechanism for platelet reduction in anti-neuropilin-1 (MNRP1685A)–treated phase I patients.. Journal of Clinical Oncology. 29(15_suppl). e13598–e13598. 10 indexed citations

13.

Chen, Weiwei, Tracy Tang, Jeff Eastham-Anderson, et al.. (2011). Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proceedings of the National Academy of Sciences. 108(23). 9589–9594. 93 indexed citations

14.

Tian, Hua, Christopher A. Callahan, Kelly DuPree, et al.. (2009). Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proceedings of the National Academy of Sciences. 106(11). 4254–4259. 332 indexed citations

15.

Kelley, Sean K., Thomas Gelzleichter, Dong Xie, et al.. (2006). Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates. British Journal of Pharmacology. 148(8). 1116–1123. 46 indexed citations

16.

Walder, Claire E., Simon P. Green, Walter C. Darbonne, et al.. (1997). Ischemic Stroke Injury Is Reduced in Mice Lacking a Functional NADPH Oxidase. Stroke. 28(11). 2252–2258. 292 indexed citations

17.

Neote, Kuldeep, Walter C. Darbonne, John R. Ogez, Richard Horuk, & Thomas J. Schall. (1993). Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. Journal of Biological Chemistry. 268(17). 12247–12249. 231 indexed citations

18.

Horuk, Richard, Timothy J. Colby, Walter C. Darbonne, Thomas J. Schall, & Kuldeep Neote. (1993). The human erythrocyte inflammatory peptide (chemokine) receptor. Biochemical characterization, solubilization, and development of a binding assay for the soluble receptor. Biochemistry. 32(22). 5733–5738. 78 indexed citations

19.

Darbonne, Walter C., Glenn C. Rice, M Möhler, et al.. (1991). Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin.. Journal of Clinical Investigation. 88(4). 1362–1369. 372 indexed citations

20.

Ramakrishnan, Vijay, Dominick Sinicropi, Ruhee Dere, et al.. (1990). Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers.. Journal of Biological Chemistry. 265(5). 2755–2762. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact